Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London
ImmunityBio, Inc. recently presented at the Jefferies London Healthcare Conference 2025, sharing updates on its latest performance and product developments at the ME Hotel in London.
A noteworthy highlight was the company’s significant third-quarter product revenue growth, driven by strong commercial demand for Anktiva in combination with BCG for BCG-unresponsive NMIBC with CIS.
We’ll explore how robust Anktiva product uptake and higher revenue impact ImmunityBio’s investment narrative and...
